[

balram bhargava

]
The third clinical trial of Covaxin BB152 had been completed as all the 25,800 volunteers involved in the exercise had been administered both doses.(Bloomberg)

India's Covid-19 vaccines will be effective against new variants, says ICMR

ANI, Thiruvananthapuram
PUBLISHED ON FEB 19, 2021 10:16 AM IST
Dr Balram Bhargava, Director General of ICMR, said a paper on Covaxin's neutralisation potential against the UK strain has been accepted for publication.
Close
Healthcare workers during a mock drill for dry run of Covid-19 vaccination programme, at MMG hospital in Ghaziabad on Tuesday.(Sakib Ali/HT Photo)
Healthcare workers during a mock drill for dry run of Covid-19 vaccination programme, at MMG hospital in Ghaziabad on Tuesday.(Sakib Ali/HT Photo)

‘Bharat Biotech vaccine approved in clinical trial mode, consent of participants has to be taken’: ICMR

By hindustantimes.com | Edited by: Amit Chaturvedi | Hindustan Times, New Delhi
UPDATED ON JAN 06, 2021 10:17 AM IST
Industry experts and some opposition leaders have expressed concern over the absence of Phase 3 trial data on Covaxin.
Close
Health experts were asked which vaccines they would lie to take between Covishield and Covaxin. (Photo: PIB)
Health experts were asked which vaccines they would lie to take between Covishield and Covaxin. (Photo: PIB)

‘Will take that vaccine...’: Experts explain why Bharat Biotech’s vaccine got approval

By hindustantimes.com | Edited by Poulomi Ghosh | Hindustan Times, New Delhi
UPDATED ON JAN 05, 2021 09:38 PM IST
Government experts on Tuesday clarified why Covaxin has been given the nod for restricted emergency use.
Close
Dr Balram Bhargava on Sunday said Covaxin might be more effective to fight the new strain of virus.(ANI)
Dr Balram Bhargava on Sunday said Covaxin might be more effective to fight the new strain of virus.(ANI)

‘2 vaccines a result proactive approach,’ says DG-ICMR

By Rhythma Kaul | Hindustan Times, New Delhi
UPDATED ON JAN 04, 2021 05:48 AM IST
“These kinds of approvals are purely data-driven, and in both these vaccines Phase 2 immunogenicity has been well established. The question of approving a vaccine without adequate data does not arise as the expert panel minutely scans the national as well international data presented to them before granting an approval,” said DG-ICMR.
Close
Union health minister Harsh Vardhan during a mock drill and dry run of Covid-19 vaccination at a model Covid-19 vaccination centre in Ansari Road, New Delhi on Saturday.(Sanchit Khanna/HT PHOTO)
Union health minister Harsh Vardhan during a mock drill and dry run of Covid-19 vaccination at a model Covid-19 vaccination centre in Ansari Road, New Delhi on Saturday.(Sanchit Khanna/HT PHOTO)

Bharat Biotech vaccine more likely to work against newer strains like UK variant: Vardhan

By Press Trust of India | Posted by Kanishka Sarkar | New Delhi
UPDATED ON JAN 04, 2021 12:08 AM IST
India’s drugs regulator on Sunday approved Oxford Covid-19 vaccine Covishield, manufactured by the Serum Institute, and indigenously developed Covaxin of Bharat Biotech for restricted emergency use in the country, paving the way for a massive inoculation drive.
Close
Dr Balram Bhargava on Sunday said Covaxin might be more effective to fight the new strain of virus. (Photo: ANI)
Dr Balram Bhargava on Sunday said Covaxin might be more effective to fight the new strain of virus. (Photo: ANI)

‘Bharat Biotech vaccine may have some advantages...’: ICMR chief on Covaxin, mutant strain

By hindustantimes.com | Edited by Poulomi Ghosh | Hindustan Times, New Delhi
UPDATED ON JAN 03, 2021 08:16 PM IST
Covaxin is a whole virion inactivated Covid-19 vaccine while Oxford vaccine works differently — it produces surface spike protein priming the immune system to attack the SARS-CoV-2 virus if it later infects the body.
Close
Dr. Balram Bhargava.(ANI)
Dr. Balram Bhargava.(ANI)

Experimental therapies not to be used indiscriminately, warns ICMR

By Rhythma Kaul | Hindustan Times, New Delhi
UPDATED ON DEC 30, 2020 01:59 AM IST
The warning comes in the backdrop of the discovery in the UK of a new variant of the virus that causes Covid-19. The new strain, scientists say, is more transmissible than the original one.
Close
Speaking in the context of UK Covid-19 virus strain mutation, Dr Bhargava said genetic mutations occur in the respiratory viruses but higher transmissibility is a point of concern.(ANI)
Speaking in the context of UK Covid-19 virus strain mutation, Dr Bhargava said genetic mutations occur in the respiratory viruses but higher transmissibility is a point of concern.(ANI)

Non-judicious use of therapies for Covid-19 leads to virus mutations: ICMR chief

By Asian News International | Posted by Srivatsan K C | New Delhi
PUBLISHED ON DEC 29, 2020 09:03 PM IST
“Those therapies which are being touted as ‘anti-viral’ or ‘anti-COVID therapies’ and they have do not have benefits established in a scientific research paper, those therapies should not be used as they will put tremendous immune pressure on the virus and it will tend to mutate more, Dr Bhargava told ANI.
Close
DG, ICMR Dr. Balram Bhargava addressing a press conference on the actions taken, preparedness, and updates on Covid-19 in New Delhi.(ANI file photo)
DG, ICMR Dr. Balram Bhargava addressing a press conference on the actions taken, preparedness, and updates on Covid-19 in New Delhi.(ANI file photo)

ICMR chief Balram Bhargava admitted to AIIMS Trauma Centre for Covid-19 treatment

By hindustantimes.com | Edited by Arpan Rai | Hindustan Times, New DElhi
UPDATED ON DEC 18, 2020 10:40 PM IST
Bhargava, who was admitted to the AIIMS Trauma Centre, is recovering well and likely to be discharged soon, the report added.
Close
A DCD volunteer wearing face mask walks past a mural on novel coronavirus and protective measures, in New Delhi, on November 24.(PTI File Photo)
A DCD volunteer wearing face mask walks past a mural on novel coronavirus and protective measures, in New Delhi, on November 24.(PTI File Photo)

‘Need to follow Covid-19 protocol even after vaccine is available, masks here to stay’: ICMR chief

By hindustantimes.com | Edited by: Amit Chaturvedi | HIndustan Times, New Delhi
UPDATED ON NOV 29, 2020 09:10 AM IST
Speaking at a webinar hosted by Lucknow’s King George’s Medical University on Saturday, professor Balram Bhargava said that India is making rapid progress as far as the development of Covid-19 vaccine is concerned.
Close
Delhi health minister Satyendar Jain.(PTI)
Delhi health minister Satyendar Jain.(PTI)

Delhi health minister Satyendar Jain bats for plasma therapy

By Anonna Dutt | Hindustan Times, New Delhi
UPDATED ON OCT 22, 2020 06:41 AM IST
ICMR had conducted a pan-India study to determine the role of plasma therapy, and the Union health ministry had added it as one of the investigational therapies in the national protocol for treating Covid-19 patients.
Close
BMC health workers collect plasma samples from patients who recovered from Covid-19, They come forward to donate blood for the convalescent plasma therapy at Dharavi in Mumbai.(Vijayanand Gupta/HT Photo)
BMC health workers collect plasma samples from patients who recovered from Covid-19, They come forward to donate blood for the convalescent plasma therapy at Dharavi in Mumbai.(Vijayanand Gupta/HT Photo)

Plasma therapy may not be used on patients

By Rhythma Kaul | Hindustan Times, New Delhi
UPDATED ON OCT 21, 2020 02:33 AM IST
ICMR had conducted a pan-India study to determine the role of plasma therapy, and the Union health ministry had added it as one of the investigational therapies in the national protocol for treating Covid-19 patients.
Close
An auto rickshaw drives past a mural depicting frontline workers fighting against Covid-19 in New Delhi.(AP)
An auto rickshaw drives past a mural depicting frontline workers fighting against Covid-19 in New Delhi.(AP)

30 million frontline workers to get Covid-19 vaccine in phase 1

By Rhythma Kaul | Hindustan Times, New Delhi
UPDATED ON OCT 21, 2020 01:35 AM IST
The 30 million include 7 million doctors and paramedics, in addition to 20 million other frontline health workers, Union health secretary Rajesh Bhushan said on the sidelines of a Covid-19 media briefing on Tuesday.
Close
ICMR Director-General Balram Bhargava opined that Gandhi was aware and concerned about individual health(Virendra Singh Gosain/HT File Photo)
ICMR Director-General Balram Bhargava opined that Gandhi was aware and concerned about individual health(Virendra Singh Gosain/HT File Photo)

ICMR DG hails Gandhian perspective of healthy living in Covid-19 times

By Asian News International | Posted by Kanishka Sarkar | New Delhi
UPDATED ON OCT 03, 2020 10:13 AM IST
he ICMR Director-General opined that Gandhi was aware and concerned about individual health and poured his thoughts in the book “Key to Health”.
Close
People wearing protective face masks wait in line to get tested for the coronavirus disease (Covid-19), in New Delhi.(Reuters)
People wearing protective face masks wait in line to get tested for the coronavirus disease (Covid-19), in New Delhi.(Reuters)

Covid-19: Key highlights of second sero-survey findings

By hindustantimes.com | Edited by Shivani Kumar | Hindustan Times, New Delhi
UPDATED ON SEP 29, 2020 07:40 PM IST
As per the findings, a considerable population still vulnerable to Covid-19 which has killed over 96,300 people across the country.
Close
Delhi Lt. Governor Anil Baijal addressing a digital press conference over lockdown amid coronavirus pandemic in New Delhi.(@AamAadmiParty/Twitter File Photo)
Delhi Lt. Governor Anil Baijal addressing a digital press conference over lockdown amid coronavirus pandemic in New Delhi.(@AamAadmiParty/Twitter File Photo)

Delhi LG asks expert panel to suggest measures to tackle Covid-19 situation: Report

By Press Trust of India | Posted by Kanishka Sarkar | New Delhi
PUBLISHED ON SEP 22, 2020 06:33 PM IST
Delhi recorded 4,071 cases on September 19; 4,127 on September 18; 4,432 on September 17; 4,473 on September 16 and 4,263 on September 15.
Close
Healthcare workers during Covid-19 screening and swab test at Kandivali(W) in Mumbai on Tuesday.(Satyabrata Tripathy/HT Photo)
Healthcare workers during Covid-19 screening and swab test at Kandivali(W) in Mumbai on Tuesday.(Satyabrata Tripathy/HT Photo)

India’s Covid-19 recovery rate surges past 78%, one of the highest globally: Govt

By hindustantimes.com| Edited by Kanishka Sarkar | Hindustan Times, New Delhi
UPDATED ON SEP 15, 2020 10:25 PM IST
As of Tuesday, 3,859,399 people had recovered from Covid-19 and the country’s recovery tally exceeded the active cases by 2,869,338.
Close
What makes a daredevil expect a favourable outcome, of not getting infected, despite reckless behaviour?(Raj K Raj/HT PHOTO)
What makes a daredevil expect a favourable outcome, of not getting infected, despite reckless behaviour?(Raj K Raj/HT PHOTO)

Covid-19: The daredevils who defy scientific advice

By Payal S Kapoor
UPDATED ON AUG 30, 2020 09:14 PM IST
Many continue to go about their lives, refusing to follow simple preventive health guidelines, as if the world is already in a post-pandemic era
Close
Two vaccine candidates in the fray were shortlisted after successful toxicity studies in animals.(Representative image/REUTERS)
Two vaccine candidates in the fray were shortlisted after successful toxicity studies in animals.(Representative image/REUTERS)

Clinical study of Covid-19 vaccine on human volunteers now in India

By hindustantime.com| Edited by Sabir Hussain | Hindustan Times, New Delhi
UPDATED ON JUL 14, 2020 06:38 PM IST
Two pharmaceutical companies are carrying out clinical studies on approximately 1,000 human volunteers each at different sites.
Close
A priest and a labourer wear personal protective equipment (PPE) at a crematorium, amid the spread of the coronavirus disease in New Delhi, India, July 3, 2020.(REUTERS)
A priest and a labourer wear personal protective equipment (PPE) at a crematorium, amid the spread of the coronavirus disease in New Delhi, India, July 3, 2020.(REUTERS)

The intersection of politics and science, writes Chanakya

By Chanakya | Hindustan Times
UPDATED ON JUL 05, 2020 06:03 AM IST
The two most powerful tools in any country’s armoury, when it comes to fighting the Covid-19 pandemic, are data and science, and political leaders through the centuries have had an uncomfortable relationship with both.
Close
At 2.7 million new infections, India is home to almost a quarter of the world’s TB patients. The Indian government has set an ambitious target of eliminating the disease by 2025- five years before the global target. (Image used for representation).(Getty Images/iStockphoto.)
At 2.7 million new infections, India is home to almost a quarter of the world’s TB patients. The Indian government has set an ambitious target of eliminating the disease by 2025- five years before the global target. (Image used for representation).(Getty Images/iStockphoto.)

WHO approves India’s cost-effective TB test

By HT Correspondent | Hindustan Times, New Delhi
UPDATED ON JAN 17, 2020 12:37 AM IST
The WHO’’s Global TB Programme has included TrueNat TB test, a new molecular test that detects TB as well as resistance to the drug Rifampicin in about 90 minutes, in its rapid communication document on molecular investigative procedure in laboratory medicine and pharmacology.
Close
the National Aids Research Institute (NARI) is set to drop its focus on research into the Acquired Immuno-deficiency Syndrome (Aids) and also undergo a name change in the coming months.(HT Photo)
the National Aids Research Institute (NARI) is set to drop its focus on research into the Acquired Immuno-deficiency Syndrome (Aids) and also undergo a name change in the coming months.(HT Photo)

National Aids Research Institute to drop focus on HIV, undergo name change

By Nozia Sayyed | Pune
UPDATED ON FEB 17, 2019 07:45 AM IST
NARI director Dr Samiran Panda said in an interview that this was among the issues discussed during the February 8 visit by ICMR (Indian Council of Medical Research) director Dr Balram Bhargava to the institute at Bhosari, Pune.
Close
SHARE
Story Saved